Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.25. Hemispherx BioPharma shares last traded at $0.22, with a volume of 864,053 shares changing hands.
Hemispherx BioPharma Stock Performance
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than Hemispherx BioPharma
- Technology Stocks Explained: Here’s What to Know About Tech
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Top-Performing Non-Leveraged ETFs This Year
- P/E Ratio Calculation: How to Assess Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
